[HTML][HTML] Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease

J Lun, H Zhang, J Guo, M Yu, J Fang - Frontiers in Pharmacology, 2023 - frontiersin.org
Inflammatory bowel disease (IBD) is a chronic disease that is characterized by intestinal
inflammation. Epithelial damage and loss of intestinal barrier function are believed to be the …

[HTML][HTML] Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease—Clinical Practice Position Statement of the Polish Society of Nephrology

T Stompór, M Adamczak, I Kurnatowska… - Journal of Clinical …, 2023 - mdpi.com
Chronic kidney disease (CKD) is a modern epidemic worldwide. Introducing renin–
angiotensin system (RAS) inhibitors (ie, ACEi or ARB) not only as blood-pressure-lowering …

A Rationally Designed Complex Replenishes the Transferrin Iron Pool Directly and with High Specificity

A Sargun, AL Fisher, AS Wolock, S Phillips… - Journal of the …, 2023 - ACS Publications
Many forms of anemia are caused or complicated by pathologic restriction of iron (Fe).
Chronic inflammation and certain genetic mutations decrease the activity of ferroportin, the …

Renal anemia: Current treatments and emerging molecules

M Heras-Benito - Revista Clínica Española (English Edition), 2023 - Elsevier
Anemia is a common complication of kidney disease and the prevalence increases as the
disease progresses. It worsens the quality of life of patients and increases morbidity and …

[HTML][HTML] The efficacy and safety of roxadustat for the treatment of posttransplantation anemia: a randomized study

W Kong, X Wu, Z Shen, M Wang, X Liu, X Lin… - Kidney International …, 2024 - Elsevier
Introduction Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH)
inhibitor, can stimulate erythropoiesis. Our objective was to evaluate the efficacy and safety …

[HTML][HTML] Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study

C Jin, Y Zhang, C Luo, Y Ren, B Ye, X Hu… - Translational …, 2022 - ncbi.nlm.nih.gov
Background Renal anemia is a common complication in patients with end-stage renal
disease (ESRD). Both roxadustat and recombinant human erythropoietin (rhEPO) are …

[HTML][HTML] A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses

Y Shi, Y Zhao, W Liang, B Zhang, R Kang, W Yang… - Annals of …, 2024 - Springer
Some aplastic anemia (AA) patients only have partial hematological responses after
immunosuppressive therapy. Failure to achieve complete normalization of blood counts …

Anemia renal: tratamientos actuales y moléculas emergentes

M Heras-Benito - Revista Clínica Española, 2023 - Elsevier
La anemia es una complicación frecuente de la enfermedad renal cuya prevalencia
aumenta a medida que progresa la enfermedad, empeora la calidad de vida de pacientes y …

[PDF][PDF] Munuaisten vajaatoiminta ja anemia

S Mäkelä - 2023 - trepo.tuni.fi
Kroonista munuaistautia sairastavan potilaan anemia on yleinen löydös. Tärkeimmät syyt
ovat erytro poietiinin ja raudanpuute. Raudanpuute voi olla joko absoluuttista tai …

[HTML][HTML] Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications

T Fang, C Ma, Z Zhang, L Sun, N Zheng - Frontiers in Pharmacology, 2023 - frontiersin.org
Diabetes mellitus (DM) is a group of metabolic diseases caused by absolute or relative
deficiency of insulin secretion and characterized by chronic hyperglycemia. Its complications …